Trial Profile
Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Vorolanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors AnewPharma
- 08 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.
- 06 Jun 2017 Results (n=22) assessing the safety, tolerability, pharmacokinetics, and preliminary efficacy of CM082 in combination with everolimus in patients with metastatic renal cell carcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 20 Oct 2015 New trial record